Jan 12 (Reuters) - Moderna Inc (MRNA.O) said on Wednesday it expects to report data from its COVID-19 vaccine trial in children aged between 2 to 5 years in March. "If the data is supportive and subject to regulatory consultation, Moderna may proceed with regulatory filings for children 2-5 years of age thereafter," the company said. (https://bit.ly/3nksOES) Moderna"s vaccine, based on the messenger RNA platform, already has authorizations in Europe, UK, Australia, and Canada for adolescents aged 12-17 years, and has submitted applications for children in 6 to 11 years. In the United States, the vaccine is authorized by Food and Drug Administration as primary two-dose regimen and booster dose for adults 18 years and older. The company, however, is yet to get an authorization from the regulator for use of its vaccine in children.